Health consequences of short- and long-term postmenopausal hormone therapy

Clinical Chemistry

Volumn 42, Issue 8 SPEC. ISS., 1996, Pages 1342-1344

  Weiss, Noel S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

bone fracture; breast cancer; endometrial cancer; estrogen; myocardial infarction; progestogen

Indexed keywords

ESTROGEN;

BREAST CANCER; CANCER RISK; CONFERENCE PAPER; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HEART INFARCTION; HUMAN; POSTMENOPAUSE; RISK ASSESSMENT;

EID: 0029788524     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.8.1342     Document Type: Conference Paper

References (17)

1. Herrinton LJ, Weiss NS. Postmenopausal unopposed estrogens-characteristics of use in relation to the risk of endometrial carcinoma. Ann Epidemiol 1993;3:308-18.
2. Chu J, Schweid AI, Weiss NS. Survival among women with endometrial cancer: a comparison of estrogen users and nonusers. Am J Obstet Gynecol 1982;143:569-73.
3. Brinton LA, Shairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 1993;15:66-79.
4. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
5. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle aged women. JAMA 1995;274:137-42.
6. Newcomb P, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995;142:788-95.
7. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease; 10-year follow-up from the Nurses Health Study. N Engl J Med 1991;325:756-62.
8. Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol 1993;137:54-63.
9. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
10. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
11. Finkle WD, Greenland S, Miettinen OS, Ziel HK. Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens. Cancer Causes Control 1995;6:99-102.
12. Steinberg KK, Thacker SP, Smith J, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.
13. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? From the bedside to bench. Circulation 1995;92:5-8.
14. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
15. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
16. Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Lithell H, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-8.
17. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333.